The impact of HLA-DRB alleles on the subclass titres of antibodies against citrullinated peptides

Rheumatology

Volumn 49, Issue 10, 2010, Pages 1862-1866

  Engelmann, Robby ^a   Eggert, Martin ^b   Neeck, Gunther ^b   Mueller hilke, Brigitte ^a  

^a UNIVERSITY OF ROSTOCK   (Germany)

^b Hospital Bad Doberan   (Germany)

Author keywords

Cyclic citrullinated peptide; Human leucocyte antigen; IgG subclasses; Mutated citrullinated vimentin; Rheumatoid arthritis

Indexed keywords

CYCLIC CITRULLINATED PEPTIDE ANTIBODY; EPITOPE; HLA DR ANTIGEN; IMMUNOGLOBULIN; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G3; VIMENTIN;

ADULT; AGED; ANTIBODY TITER; ARTICLE; BLOOD ANALYSIS; DISEASE COURSE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE DOSAGE; GENE SEQUENCE; HAPLOTYPE; HUMAN; IMMUNOLOGICAL SYNAPSE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS;

ADULT; AGED; AGED, 80 AND OVER; ALLELES; ARTHRITIS, RHEUMATOID; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HLA-DR ANTIGENS; HUMANS; MALE; MIDDLE AGED; PEPTIDES, CYCLIC; VIMENTIN;

EID: 77956857330     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/keq179     Document Type: Article

References (20)

1. Gregersen P, Silver J, Winchester R. The shared epitope hypothesis. An approach to understanding the molecular genetics of susceptibility to rheumatoid arthritis. Arthritis Rheum 1987;30:1205-13.
2. Czerwony G, Alten R, Gromnica-Ihle E et al. Differential surface expression of HLA-DRB1 and HLA-DRB4 among peripheral blood cells of DR4 positive individuals. Hum Immunol 1999;60:1-9.
3. Baumgart M, Moos V, Schuhbauer D, Muller B. Differential expression of major histocompatibility complex class II genes on murine macrophages associated with T cell cytokine profile and protective/suppressive effects. Proc Natl Acad Sci USA 1998;95:6936-40.
4. Rantapää-Dahlqvist S, de Jong B, Berglin E et al. Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis. Arthritis Rheum 2003;48:2741-9.
5. Ronnelid J, Wick M, Lampa J et al. Longitudinal analysis of citrullinated protein/peptide antibodies (anti-CP) during 5 year follow up in early rheumatoid arthritis: anti-CP status predicts worse disease activity and greater radiological progression. Ann Rheum Dis 2005;64:1744-9.
6. Gorman JD, Lum RF, Chen JJ, Suarez-Almazor ME, Thomson G, Criswell LA. Impact of shared epitope genotype and ethnicity on erosive disease: a meta-analysis of 3,240 rheumatoid arthritis patients. Arthritis Rheum 2004;50:400-12.
7. Lundström E, Källberg H, Alfredsson L, Klareskog L, Padyukov L. Gene-environment interaction between the DRB1 shared epitope and smoking in the risk of anti-citrullinated protein antibody-positive rheumatoid arthritis: all alleles are important. Arthritis Rheum 2009;60: 1597-603.
8. Gourraud P, Dieude P, Boyer J et al. A new classification of HLA-DRB1 alleles differentiates predisposing and protective alleles for autoantibody production in rheumatoid arthritis. Arthritis Res Ther 2007; 9:R27.
9. Lee H, Irigoyen P, Kern M et al. Interaction between smoking, the shared epitope, and anti-cyclic citrullinated peptide: a mixed picture in three large North American rheumatoid arthritis cohorts. Arthritis Rheum 2007;56: 1745-53.
10. Engelmann R, Brandt J, Eggert M et al. IgG1 and IgG4 are the predominant subclasses among auto-antibodies against two citrullinated antigens in RA. Rheumatology 2008;47:1489-92.
11. Sutton V, Kienzle B, Knowles R. An altered splice site is found in the DRB4 gene that is not expressed in HLA-DR7, Dw11 individuals. Immunogenetics 1989;29:317-22.
12. Muller-Hilke B, Mitchison N. The role of HLA promoters in autoimmunity. Curr Pharm Des 2006;12:3743-52.
13. Weyand C, McCarthy T, Goronzy J. Correlation between disease phenotype and genetic heterogeneity in rheumatoid arthritis. J Clin Invest 1995;95:2120-6.
14. van der Helm-van Mil AH, Verpoort K, le CS, Huizinga T, de Vries R, Toes R. The HLA-DRB1 shared epitope alleles differ in the interaction with smoking and predisposition to antibodies to cyclic citrullinated peptide. Arthritis Rheum 2007;56:425-32.
15. Hosken NA, Shibuya K, Heath AW, Murphy KM, O'Garra A. The effect of antigen dose on CD4+ T helper cell phenotype development in a T cell receptor-alpha beta-transgenic model. J Exp Med 1995; 182:1579-84.
16. Zhao X, Okeke NL, Sharpe O et al. Circulating immune complexes contain citrullinated fibrinogen in rheumatoid arthritis. Arthritis Res Ther 2008;10:R94.
17. Koivula M, Aman S, Karjalainen A, Hakala M, Risteli J. Are there autoantibodies reacting against citrullinated peptides derived from type I and type II collagens in patients with rheumatoid arthritis? Ann Rheum Dis 2005; 64:1443-50.
18. Solomon S, Kassahn D, Illges H. The role of the complement and the Fc gamma R system in the pathogenesis of arthritis. Arthritis Res Ther 2005;7: 129-35.
19. Mettal D, Brune K, Mollenhauer J. Cytotoxic effects of rheumatoid arthritis sera on chondrocytes. Biochim Biophys Acta 1992;1138:85-92.
20. Nakagawa K, Sakiyama H, Tsuchida T et al. Complement C1s activation in degenerating articular cartilage of rheumatoid arthritis patients: immunohistochemical studies with an active form specific antibody. Ann Rheum Dis 1999;58:175-81.